Blueprint Medicines Investor Relations Material
Latest events
Q1 2025
Blueprint Medicines
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Blueprint Medicines Corp
Access all reports
Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies for genomically defined cancers and rare diseases. The company utilizes precision medicine approaches to design small-molecule drugs that inhibit specific genetic drivers of disease. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Blueprint Medicines Corp
Q4 2024
Blueprint Medicines Corp
Q4 2024
Blueprint Medicines Corp
Latest articles
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
Ticker symbol
BPMC
Country
🇺🇸 United States